期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

^(99)Tc^m标记的混配放射性药物研究进展

Development of ^(99)Tc^m Labelled Mixed-ligand Complexes
下载PDF
导出
摘要 99Tcm标记的混配放射性药物是近年来核医学领域中新兴的一类显像剂。本文介绍了“3+1”型、“4+1”型、“3+1+1”型、“4+1+1”型和“2+2”型混配放射性药物的化学结构、生物分布及其优缺点。这几种类型的混配药物中,尤以“2+2”型混配药物的化学、生物学特性为好,更具有良好的应用前景。 Recently, mixed-ligand technetium complexes are the novel tracers in nuclear medicine. Some 99 Tcm complexes with different ligands are reviewed,which include ＂3＋ 1＂, ＂4＋ 1＂ ,＂3＋ 1 ＋ 1＂, ＂4 ＋ 1 ＋ 1＂and ＂2 ＋ 2＂, their chemical properties, biodistribution and their limits are also discussed. Amone these ligands, the type of ＂2＋2＂ has the best characteristic of chemical and biology, and shows potential application values.
作者 张瑜 褚泰伟 王祥云
机构地区 北京大学化学与分子工程学院
出处 《同位素》 CAS 北大核心 2007年第1期52-56,共5页 Journal of Isotopes
基金 国家自然科学基金资助项目(20301001)
关键词 混配放射性药物 显像剂 ^99TC^M标记 mixed-ligand complexes imaging agents ^99Tc^m labeling
分类号 O615.42 [理学—无机化学]
  • 相关文献

参考文献23

  • 1PIETZSCH HJ,SPIES H,HAFFMANN S.Lipophilic Technetium Complexes.VI.Neutral Oxotechnetium(V) Complexes With Tridentate Dithiole/monothiole Ligand Coordination[J].Inorg Chim Acta,1989,165:163-166.
  • 2WüST F,CARLSON KE,KATZENELLENBOGEN JA,et al.Synthesis and Binding Affinities of New 17a-substituted Estradiol-Rhenium "n+ 1" Mixed-ligand and Thioethercarbonyl Complexes[J].Steroids,1998,63:665-671.
  • 3SPIES H,FIETZ H,GLASER M,et al.The "n +1" Concept in the Synthesis Strategy of Novel Technetium and Rhenium Tracers[C]// Nicolini M,Bandoli G,Mazzi U,eds.Technetium and Rhenium in Chemistry and Nuclear Medicine 4.Italy,Padova:SGEditoriali,1995:243-246.
  • 4MEEGALLA SK,PLOèSSL K,KUNG M-P,et al.The First Example of a Tc-99m Complex as a Dopamine Transporter Imaging Agent[J].J Am Chem Soc,1995,117:11 037 -11 038.
  • 5JOHANNSEN B,SCHEUNEMANN M,SPIES H,et al.Technetium(V) and Rhenium(V) Complexes for 5-HT2A Serotonin Receptor Binding:Structure-affinity Considerations[J].Nucl Med Biol,1996,23:429-438.
  • 6JOHANNSEN B,BERGER R,BRUST P,et al.Structural Modification of Receptor-binding Technetium-99m Complexes in Order to Improve Brain Uptake[J].Eur J Nucl Med,1997,24:316-319.
  • 7PIRMETTIS IC,PAPADOPOULOS MS,MASTROSTAMATIS SG,et al.Synthesis and Characterization of Oxotechnetium (V) Mixed-ligand Complexes Containing a Tridentate N-substituted Bis (2-mercaptoethyl)amine and a Monodentate Thiol[J].Inorg Chem,1996,35:1 685-1 691.
  • 8唐秀欢,王武尚.^(99)Tc^m标记"3+1"混配放射性药物设计及进展[J].同位素,2002,15(4):219-228. 被引量：2
  • 9SYHRE R,SEIFERT S,SPIES H,et al.Stability Versus Reactivity of "3+ 1" Mixed-ligand Technetium-99m Complexes in Vitro and in Vivo[J].Eur J Nucl Med,1998,25:793-796.
  • 10NOCK BA,MAINA T,YANNOUKAKOS D,et al.Glutathionemediated Metabolism of Technetium-99m SNS/S Mixed Ligand Complexes:a Proposed Mechanism of Brain Retention[J].J Med Chem,1999,42:1 066-1 075.

二级参考文献52

  • 1王世真.受体学是核医学研究的重要方向[J].中华核医学杂志,1997,17:197-197.
  • 2Seifert S, Pietzsch H-J, Scheunemann M, et al. No Carrier Added Preparation of "3+1" Mixed-ligand 99Tcm Complexes[J]. Appl Radiat Isot, 1998, 49(2):5～11.
  • 3Johannsen B, Berger R, Brust P, et al. Structural Modification of Receptor -Binding Technetium-99m Complexes in Order to Improve Brain Uptake[J]. Eur J Nucl Med, 1997, 24:316～319.
  • 4Pietzsch HJ, Scheunemann M, Kretzschmar M, et al. Synthesis and Autoradiographic Evaluation of a Novel High-affinity Tc-99m Ligand for the 5-HT2A Receptor[J]. Nucl Med Biol, 1999, 26:865～875.
  • 5Leon A, Rey A, Mallo L, et al. Novel Mixed Ligand Technetium Complexes as 5-HT1A Receptor Imaging Agents[J]. Nucl Med Biol, 2002, 29(2):217～226.
  • 6刘飞,贺佑丰,李洪玉, 等.99Tcm标记WAY类似物5-HT1A受体配基的实验研究[A].第八届全国放射性与标记化合物学术会议论文摘要汇编[C].北京:中国核学会同位素学会,2001.35～36.
  • 7Katzenellenbogen BS, Katzenellenbogen JA. Estrogen Receptor Transcription and Transactivation: Estrogen Receptor Alpha and Estrogen Receptor Beta: Regulation by Selective Estrogen Receptor Modulators and Importance in Breast Cancer[J]. Breast Cancer Res, 2000, 2(5): 335～344.
  • 8Katzenellenbogen JA, Coleman RE, HawkinsRA, et al. Tumor Receptor Imaging: Proceedings of the National Cancer Institute Workshop, Review of Current Work, and Prospective for Further Investigations[J]. Clin Cancer Res, 1995, 1(8): 921～932.
  • 9Wust F, Spies H, Johannsen B. Synthesis of "3+1" Mixed-ligand Oxorhenium(V) Complexes Containing Modified 3,17β-Estradiol[J]. Bioorg Med Chem Lett, 1996, 6(22):2 729～2 734.
  • 10Wust F, Scheller D, Spies H, et al. Synthesis of Oxorhenium(V) Complexes Derived From 7α-functionalized Testosterone: First Rhenium-containing Testosterone Derivatives[J]. Eur J Inorg Chem, 1998: 789～793.

共引文献6

同位素
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部